Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Somnomed Limited ( (AU:SOM) ) has shared an announcement.
SomnoMed Limited reported a strong Q4 FY25 performance with a revenue increase of 25.1% compared to the previous year, driven by growth in Europe and North America. The company is expanding its facility to increase capacity by at least 25% in FY26 and has reduced its backlog to negligible levels. A research paper confirmed the potential of their Rest Assure® device to enhance clinical care for OSA, supporting the company’s market leadership and innovation in treatment solutions.
The most recent analyst rating on (AU:SOM) stock is a Buy with a A$0.45 price target. To see the full list of analyst forecasts on Somnomed Limited stock, see the AU:SOM Stock Forecast page.
More about Somnomed Limited
SomnoMed Limited is a leading provider of oral appliance treatment solutions for sleep-related breathing disorders and obstructive sleep apnea (OSA).
Average Trading Volume: 71,817
Technical Sentiment Signal: Hold
Current Market Cap: A$148M
For a thorough assessment of SOM stock, go to TipRanks’ Stock Analysis page.